Seres Therapeutics, Inc. (MCRB)
5.28
-0.28
(-5.04%)
USD |
NASDAQ |
Sep 09, 16:00
5.28
0.00 (0.00%)
After-Hours: 18:10
Seres Therapeutics Shareholders Equity (Quarterly) : 34.53M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 34.53M |
| March 31, 2026 | 26.50M |
| December 31, 2025 | 44.22M |
| September 30, 2025 | 43.70M |
| June 30, 2025 | 32.95M |
| March 31, 2025 | 50.46M |
| December 31, 2024 | 13.78M |
| September 30, 2024 | 23.92M |
| June 30, 2024 | -87.07M |
| March 31, 2024 | -59.74M |
| December 31, 2023 | -44.86M |
| September 30, 2023 | -15.12M |
| June 30, 2023 | 22.61M |
| March 31, 2023 | -47.87M |
| December 31, 2022 | 10.78M |
| September 30, 2022 | 67.58M |
| June 30, 2022 | 23.06M |
| March 31, 2022 | 80.96M |
| December 31, 2021 | 131.51M |
| September 30, 2021 | 175.74M |
| June 30, 2021 | 101.07M |
| March 31, 2021 | 143.70M |
| December 31, 2020 | 174.75M |
| Date | Value |
|---|---|
| September 30, 2020 | 188.05M |
| June 30, 2020 | -65.58M |
| March 31, 2020 | -61.65M |
| December 31, 2019 | -48.32M |
| September 30, 2019 | -32.22M |
| June 30, 2019 | -17.97M |
| March 31, 2019 | -69.83M |
| December 31, 2018 | -48.04M |
| September 30, 2018 | -30.56M |
| June 30, 2018 | -13.26M |
| March 31, 2018 | 10.03M |
| December 31, 2017 | 60.70M |
| September 30, 2017 | 85.51M |
| June 30, 2017 | 87.93M |
| March 31, 2017 | 111.45M |
| December 31, 2016 | 132.63M |
| September 30, 2016 | 154.00M |
| June 30, 2016 | 167.40M |
| March 31, 2016 | 189.83M |
| December 31, 2015 | 205.39M |
| September 30, 2015 | 222.20M |
| June 30, 2015 | 94.91M |
| March 31, 2015 | 102.81M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Agenus, Inc. | -199.08M |
| Amgen, Inc. | 11.69B |
| Anika Therapeutics, Inc. | 137.28M |
| BioCryst Pharmaceuticals, Inc. | -454.29M |
| Imunon, Inc. | 4.189M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 101.59M |
| Total Liabilities (Quarterly) | 67.05M |
| Debt to Equity Ratio | 1.640 |
| Current Ratio | 2.114 |
| Net Debt Paydown Yield | 8.49% |